Skip to main content
SpringerLink
Log in

Omalizumab: Stepping Outside Our Comfort Zone to Broaden the Number of Those Who Can Benefit

  • Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. de Llano LP, Vennera Mdel C, Alvarez FJ, et al. Effects of omalizumab in non-atopic asthma: results from a spanish multicenter registry. J Asthma. 2013;50:296–301.

    Google Scholar 

  2. Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131:110–6.

    Article  CAS  PubMed  Google Scholar 

  3. Garcia G, Magnan A, Chiron R, et al. A proof of concept randomized-controlled trial of omalizumab in patients with severe difficult to control nonatopic asthma. Chest. 2013;144(2):411–9.

    Article  CAS  PubMed  Google Scholar 

  4. Humbert M, Menz G, Ying S, Corrigan CJ, Robinson DS, Durham SR, Kay AB. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today. 1999;20(11):528–33.

    Article  CAS  PubMed  Google Scholar 

  5. Babu KS, Polosa R, Morjaria JB. Anti-IgE-emerging opportunities for omalizumab. Expert Opin Biol Ther. 2013;13:765–77.

    Article  CAS  PubMed  Google Scholar 

  6. Dullaers M, De Bruyne R, Ramadani F, Gould HJ, Gevaert P, Lambrecht BN. The who, where, and when of IgE in allergic airway disease. J Allergy Clin Immunol. 2012;129(3):635–45.

    Article  CAS  PubMed  Google Scholar 

  7. European Medicines Agency. Xolair omalizumab. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000606/human_med_001162.jsp&mid=WC0b01ac058001d124. Accessed 19 Jan 2014.

  8. Buhl R, Marco AG, Cohen D, Canonica GW. Eligibility for treatment with omalizumab in Italy and Germany. Respir Med. 2014;108(1):50-6.

    Google Scholar 

  9. Lommatzsch M, Korn S, Buhl R, Virchow JC. Against all odds: anti-IgE for intrinsic asthma? Thorax. 2014;69(1):94–6.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Domingo C. Omalizumab for severe asthma: efficacy beyond the atopic patient? Drugs. 2014.

  11. Corrigan C. Mechanisms of intrinsic asthma. Curr Opin Allergy Clin Immunol. 2004;4(1):53–6.

    Article  CAS  PubMed  Google Scholar 

  12. Humbert M, Menz G, Ying S, Corrigan CJ, Robinson DS, Durham SR, Kay AB. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today. 1999;20(11):528–33.

    Article  CAS  PubMed  Google Scholar 

  13. Pillai P, Corrigan CJ, Ying S. Airway epithelium in atopic and nonatopic asthma: similarities and differences. ISRN Allergy. 2011;2011:195846.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693–704.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110–6.e1.

    Google Scholar 

  16. Bachert C, Zhang N, Holtappels G, De Lobel L, van Cauwenberge P, Liu S, et al. Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. J Allergy Clin Immunol. 2010;126:962–8, 968.e1–6.

    Google Scholar 

  17. Sanchez J, Ramirez R, Diez S, Sus S, Echenique A, Olivares M, Cardona R. Omalizumab beyond asthma. Allergol Immunopathol (Madr). 2012;40(5):306–15.

    Article  CAS  PubMed  Google Scholar 

  18. Chanez P, Contin-Bordes C, Garcia G, Verkindre C, Didier A, De Blay F, de Lara MT, Blanco P, Moreau JF, Robinson P, Bourdeix I, Trunet P, Le Gros V, Humbert M, Molimard M. Omalizumab-induced decrease of FcεRI expression in patients with severe allergic asthma. Respir Med. 2010;104(11):1608–17.

    Article  PubMed  Google Scholar 

  19. Korn S, Haasler I, Fliedner F, et al. Monitoring free serum IgE in severe asthma patients treated with omalizumab. Respir Med. 2012;106:1494–500.

    Article  PubMed  Google Scholar 

  20. Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187:804–11.

    Article  CAS  PubMed  Google Scholar 

  21. Chung KF. New treatments for severe treatment-resistant asthma: targeting the right patient. Lancet Respir Med. 2013;1:639–52.

    Article  CAS  PubMed  Google Scholar 

  22. Amelink M, de Groot JC, de Nijs SB, Lutter R, Zwinderman AH, Sterk PJ, ten Brinke A, Bel EH. Severe adult-onset asthma: a distinct phenotype. J Allergy Clin Immunol. 2013;132:336–41.

    Article  PubMed  Google Scholar 

  23. Amelink M, de Nijs SB, de Groot JC, van Tilburg PM, van Spiegel PI, Krouwels FH, Lutter R, Zwinderman AH, Weersink EJ, ten Brinke A, Sterk PJ, Bel EH. Three phenotypes of adult-onset asthma. Allergy. 2013;68(5):674–80.

    Article  CAS  PubMed  Google Scholar 

  24. Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, McKenzie AN, Nagai H, Hotokebuchi T, Izuhara K. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol. 2006;118:98–104.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

No sources of funding were used to assist in the preparation of this commentary. Prof. Cazzola is a consultant at Novartis and a member of its speaker bureau. Andrea Segreti reports no conflicts of interest.

Author information

Authors and Affiliations

  1. Unit of Respiratory Clinical Pharmacology, Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy

    Mario Cazzola & Andrea Segreti

Authors
  1. Mario Cazzola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Segreti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mario Cazzola.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cazzola, M., Segreti, A. Omalizumab: Stepping Outside Our Comfort Zone to Broaden the Number of Those Who Can Benefit. Drugs 74, 535–537 (2014). https://doi.org/10.1007/s40265-014-0205-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-014-0205-9

Keywords

Search

Navigation